Content
March 2019, Volume 20, Issue 2
- 205-216 Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries
by M. F. Janssen & A. Szende & J. Cabases & J. M. Ramos-Goñi & G. Vilagut & H. H. König - 217-232 Design and effects of outcome-based payment models in healthcare: a systematic review
by F. P. Vlaanderen & M. A. Tanke & B. R. Bloem & M. J. Faber & F. Eijkenaar & F. T. Schut & P. P. T. Jeurissen - 233-243 The association of potentially inappropriate medication use on health outcomes and hospital costs in community-dwelling older persons: a longitudinal 12-year study
by Virva Hyttinen & Johanna Jyrkkä & Leena K. Saastamoinen & Anna-Kaisa Vartiainen & Hannu Valtonen - 245-255 Valuation of preference-based measures: can existing preference data be used to select a smaller sample of health states?
by Samer A. Kharroubi & Donna Rowen - 257-270 A new method for valuing health: directly eliciting personal utility functions
by Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout - 271-280 Pricing of HPV vaccines in European tender-based settings
by Venetia Qendri & Johannes A. Bogaards & Johannes Berkhof - 281-301 Potential savings in the treatment pathway of liver transplantation: an inter-sectorial analysis of cost-rising factors
by Lena Harries & Jill Gwiasda & Zhi Qu & Harald Schrem & Christian Krauth & Volker Eric Amelung - 303-316 Catastrophic financial effect of replacing informal care with formal care: a study based on haematological neoplasms
by Marta Ortega-Ortega & Raúl Pozo-Rubio - 317-327 Structured physiotherapy including a work place intervention for patients with neck and/or back pain in primary care: an economic evaluation
by Sanjib Saha & Birgitta Grahn & Ulf-G. Gerdtham & Kjerstin Stigmar & Sara Holmberg & Johan Jarl
February 2019, Volume 20, Issue 1
- 1-5 Future unrelated medical costs need to be considered in cost effectiveness analysis
by Pieter Baal & Alec Morton & David Meltzer & Werner Brouwer - 7-26 Are cost differences between specialist and general hospitals compensated by the prospective payment system?
by Francesco Longo & Luigi Siciliani & Andrew Street - 27-43 The health knowledge mechanism: evidence on the link between education and health lifestyle in the Philippines
by Roman Hoffmann & Sebastian Uljas Lutz - 45-57 Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
by Matthias Herpers & Charalabos-Markos Dintsios - 59-73 Unemployment, unemployment duration, and health: selection or causation?
by Johannes Stauder - 75-82 Mitigating hypothetical bias in willingness to pay studies: post-estimation uncertainty and anchoring on irrelevant information
by Ana Bobinac - 83-98 The effects of health shocks on labor market outcomes: evidence from UK panel data
by Otto Lenhart - 99-105 Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments
by Fan Yang & Nancy Devlin & Nan Luo - 107-134 Economic burden of stroke: a systematic review on post-stroke care
by S. Rajsic & H. Gothe & H. H. Borba & G. Sroczynski & J. Vujicic & T. Toell & Uwe Siebert - 135-147 The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study
by Laura Delgado-Ortega & Almudena González-Domínguez & Josep María Borrás & Juan Oliva-Moreno & Eva González-Haba & Salomón Menjón & Pedro Pérez & David Vicente & Luis Cordero & Margarita Jiménez & Susana Simón & Álvaro Hidalgo-Vega & Carlota Moya-Alarcón - 149-162 Health information and life-course smoking behavior: evidence from Turkey
by Dean R. Lillard & Zeynep Önder - 163-174 Trends and regional variation in rates of orthopaedic surgery in Germany: the impact of competition
by Natalie Baier & Lisa-Marie Sax & Leonie Sundmacher
June 2019, Volume 20, Issue 1
- 1-3 Patient-reported outcomes: opportunities and challenges in Central Europe
by Márta Péntek - 5-16 The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys
by Petra Baji & Dominik Golicki & Valentina Prevolnik-Rupel & Werner B. F. Brouwer & Zsombor Zrubka & László Gulácsi & Márta Péntek - 17-30 Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary
by Márta Péntek & Ottó Hajdu & Fanni Rencz & Zsuzsanna Beretzky & Valentin Brodszky & Petra Baji & Zsombor Zrubka & Klára Major & László Gulácsi - 31-41 Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS
by Zsombor Zrubka & Zoltán Hermann & László Gulácsi & Valentin Brodszky & Fanni Rencz & Márta Péntek - 43-55 Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary
by Fanni Rencz & Béla Tamási & Valentin Brodszky & László Gulácsi & Miklós Weszl & Márta Péntek - 57-69 Psychometric properties of the Hungarian version of the eHealth Literacy Scale
by Zsombor Zrubka & Ottó Hajdu & Fanni Rencz & Petra Baji & László Gulácsi & Márta Péntek - 71-78 Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey
by Armin Lucevic & Márta Péntek & Dionne Kringos & Niek Klazinga & László Gulácsi & Óscar Brito Fernandes & Imre Boncz & Petra Baji - 79-90 Patient experiences with outpatient care in Hungary: results of an online population survey
by Óscar Brito Fernandes & Petra Baji & Dionne Kringos & Niek Klazinga & László Gulácsi & Armin Lucevic & Imre Boncz & Márta Péntek - 91-100 Patient and general population values for luminal and perianal fistulising Crohn’s disease health states
by Fanni Rencz & Peep F. M. Stalmeier & Márta Péntek & Valentin Brodszky & Gábor Ruzsa & Lóránt Gönczi & Károly Palatka & László Herszényi & Eszter Schäfer & János Banai & Mariann Rutka & László Gulácsi & Peter L. Lakatos - 101-107 Subjective well-being in patients with pemphigus: a path analysis
by Ariel Mitev & Fanni Rencz & Béla Tamási & Krisztina Hajdu & Márta Péntek & László Gulácsi & Andrea Szegedi & Zsuzsanna Bata-Csörgő & Ágnes Kinyó & Miklós Sárdy & Valentin Brodszky - 109-117 EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review
by Valentina Prevolnik Rupel & Marko Divjak & Zsombor Zrubka & Fanni Rencz & László Gulácsi & Dominik Golicki & Dagmara Mirowska-Guzel & Judit Simon & Valentin Brodszky & Petra Baji & Jakub Závada & Guenka Petrova & Alexandru Rotar & Márta Péntek - 119-132 A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases
by Zsombor Zrubka & Zsuzsanna Beretzky & Zoltán Hermann & Valentin Brodszky & László Gulácsi & Fanni Rencz & Petra Baji & Dominik Golicki & Valentina Prevolnik-Rupel & Márta Péntek - 133-140 Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?
by Miklós Weszl & Fanni Rencz & Valentin Brodszky - 141-154 Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies
by Zsombor Zrubka & Dominik Golicki & Valentina Prevolnik-Rupel & Petra Baji & Fanni Rencz & Valentin Brodszky & László Gulácsi & Márta Péntek - 155-172 Cost-of-illness studies in nine Central and Eastern European countries
by Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi
December 2018, Volume 19, Issue 9
- 1207-1211 What should we know about the person behind a TTO?
by Floortje Nooten & Jan Busschbach & Michel Agthoven & Job Exel & Werner Brouwer - 1213-1223 Preferences for home- and community-based long-term care services in Germany: a discrete choice experiment
by T. Lehnert & O. H. Günther & A. Hajek & S. G. Riedel-Heller & H. H. König - 1225-1228 Some adjustments to the human capital and the friction cost methods
by Antonis Targoutzidis - 1229-1242 Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach
by Ann-Kathrin Richter & Ludger Klimek & Hans F. Merk & Norbert Mülleneisen & Harald Renz & Wolfgang Wehrmann & Thomas Werfel & Eckard Hamelmann & Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Janine Biermann-Stallwitz - 1243-1257 The economic impact of multiple sclerosis to the patients and their families in Norway
by B. Svendsen & N. Grytten & L. Bø & H. Aarseth & T. Smedal & K-M. Myhr - 1259-1283 Tackling the chronic disease burden: are there co-benefits from climate policy measures?
by Désirée Vandenberghe & Johan Albrecht - 1285-1301 Health inequality indices and exogenous risk factors: an illustration on Luxembourgish workers
by Stéphane Mussard & Maria Noel Pi Alperin & Véronique Thireau - 1303-1318 Cost–utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort
by Rebecca Forster & Aran Ratcliffe & Megan Lewis & Amy Crossley & Julio López Bastida & William C. N. Dunlop - 1319-1333 Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students
by Jonah Popp & John A. Nyman & Xianghua Luo & Jill Bengtson & Katherine Lust & Lawrence An & Jasjit S. Ahluwalia & Janet L. Thomas - 1335-1350 People’s perception and cost-effectiveness of home confinement during an influenza pandemic: evidence from the French case
by Caroline Orset - 1351-1363 Examining unpriced risk heterogeneity in the Dutch health insurance market
by A. A. Withagen-Koster & R. C. Kleef & F. Eijkenaar - 1365-1374 Economic evaluation of Zepatier for the management of HCV in the Italian scenario
by F. R. Rolli & M. Ruggeri & F. Kheiraoui & C. Drago & M. Basile & C. Favaretti & A. Cicchetti
November 2018, Volume 19, Issue 8
- 1035-1038 Pharmaceutical pricing conundrum: time to get rid of it?
by Livio Garattini & Anna Padula - 1039-1051 Health polarization and inequalities across Europe: an empirical approach
by Marta Pascual & David Cantarero & Paloma Lanza - 1053-1066 How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity
by Matthew Quaife & Fern Terris-Prestholt & Gian Luca Di Tanna & Peter Vickerman - 1067-1086 Testing the Grossman model of medical spending determinants with macroeconomic panel data
by Jochen Hartwig & Jan-Egbert Sturm - 1087-1110 Market structure and competition in the healthcare industry
by Martin Lábaj & Peter Silanič & Christoph Weiss & Biliana Yontcheva - 1111-1128 The earnings and employment losses before entering the disability system
by Maria Cervini-Pla & Judit Vall Castelló - 1129-1136 Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records
by Marc Casajuana & Maria Giner-Soriano & Albert Roso-Llorach & Cristina Vedia & Concepció Violan & Rosa Morros - 1137-1148 Unobserved heterogeneity in work absence
by María José Suárez & Cristina Muñiz - 1149-1161 How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts
by Simon Wieser & Marco Riguzzi & Mark Pletscher & Carola A. Huber & Harry Telser & Matthias Schwenkglenks - 1163-1172 The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
by Yang Meng & Nadine Hertel & John Ellis & Edith Morais & Helen Johnson & Zoe Philips & Neil Roskell & Andrew Walker & Dawn Lee - 1173-1187 The impact of health on wages: evidence for Europe
by Ana Rodriguez-Alvarez & César Rodriguez-Gutierrez - 1189-1205 Does freedom make a difference?
by Philippe Tessier & Josselin Thuilliez
September 2018, Volume 19, Issue 7
- 905-907 EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?
by F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas - 909-922 The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study
by Wei Yang & Heather Gage & Daniel Jackson & Monique Raats - 923-934 Health care service utilization of documented and undocumented hired farmworkers in the U.S
by Tianyuan Luo & Cesar L. Escalante - 935-943 Ebola in the Netherlands, 2014–2015: costs of preparedness and response
by Anita W. M. Suijkerbuijk & Corien M. Swaan & Marie-Josee J. Mangen & Johan J. Polder & Aura Timen & Wilhelmina L. M. Ruijs - 945-956 The impact of waiting for intervention on costs and effectiveness: the case of transcatheter aortic valve replacement
by Aida Ribera & John Slof & Ignacio Ferreira-González & Vicente Serra & Bruno García-del Blanco & Purificació Cascant & Rut Andrea & Carlos Falces & Enrique Gutiérrez & Raquel del Valle-Fernández & César Morís-de laTassa & Pedro Mota & Juan Francisco Oteo & Pilar Tornos & David García-Dorado - 957-965 Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
by Maartje S. Jacobs & Lisa A. Jong & Maarten J. Postma & Robert G. Tieleman & Marinus Hulst - 967-978 The effect of online gambling on gambling problems and resulting economic health costs in Germany
by Tobias Effertz & Anja Bischof & Hans-Jürgen Rumpf & Christian Meyer & Ulrich John - 979-991 Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review
by Lidia García-Pérez & Renata Linertová & Margarita Álvarez-de-la-Rosa & Juan Carlos Bayón & Iñaki Imaz-Iglesia & Jorge Ferrer-Rodríguez & Pedro Serrano-Aguilar - 993-1008 Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study
by Lisanne I. Lier & Judith E. Bosmans & Hein P. J. Hout & Lidwine B. Mokkink & Wilbert B. Hout & G. Ardine Wit & Carmen D. Dirksen & Henk L. G. R. Nies & Cees M. P. M. Hertogh & Henriëtte G. Roest - 1009-1017 Assessing the opportunity costs of patients with multidrug-resistant organisms in hospitals
by Claudia Hübner & Walter Ried & Steffen Flessa - 1019-1026 Threshold analysis in the presence of both the diagnostic and the therapeutic risk
by Stefan Felder & Thomas Mayrhofer - 1027-1034 Impact of specialist rehabilitation services on hospital length of stay and associated costs
by A. Duarte & C. Bojke & W. Cayton & A. Salawu & B. Case & L. Bojke & G. Richardson
July 2018, Volume 19, Issue 6
- 769-774 Does the approach to economic evaluation in health care depend on culture, values, and institutional context?
by Aleksandra Torbica & Rosanna Tarricone & Michael Drummond - 775-784 The impact of copayments on mental healthcare utilization: a natural experiment
by Timo R. Lambregts & René C. J. A. Vliet - 785-795 Uncontrolled diabetes and health care utilisation: panel data evidence from Spain
by Joan Gil & Antoni Sicras-Mainar & Eugenio Zucchelli - 797-806 Does the use of the proportional shortfall help align the prioritisation of health services with public preferences?
by Jeff Richardson & Angelo Iezzi & Aimee Maxwell & Gang Chen - 807-820 Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
by S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson - 821-830 Guidelines versus reality: is coronary stent application in three-vessel disease standard or the exception?
by Roland Linder & J. Zeidler & F. Verheyen & J.-M. Graf Schulenburg & A. Haverich & T. Schilling - 831-842 Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death?
by Nisha C. Hazra & Caroline Rudisill & Martin C. Gulliford - 843-860 Predicting medical practices using various risk attitude measures
by Sophie Massin & Antoine Nebout & Bruno Ventelou - 861-870 A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy
by Ben F. M. Wijnen & Iris Mosweu & Marian H. J. M. Majoie & Leone Ridsdale & Reina J. A. Kinderen & Silvia M. A. A. Evers & Paul McCrone - 871-880 Estimating a constant WTP for a QALY—a mission impossible?
by Björn Sund & Mikael Svensson - 881-891 Experience-based utility and own health state valuation for a health state classification system: why and how to do it
by John Brazier & Donna Rowen & Milad Karimi & Tessa Peasgood & Aki Tsuchiya & Julie Ratcliffe - 893-904 Cost–utility and cost-effectiveness of physical exercise during adjuvant chemotherapy
by Hanna Waart & Johanna M. Dongen & Wim H. Harten & Martijn M. Stuiver & Rosalie Huijsmans & Jeannette A. J. H. Hellendoorn-van Vreeswijk & Gabe S. Sonke & Neil K. Aaronson
June 2018, Volume 19, Issue 5
- 637-640 Patient empowerment in Europe: is no further research needed?
by Livio Garattini & Anna Padula - 641-651 Health-related quality of life associated with bullying and aggression: a cross-sectional study in English secondary schools
by Catherine Fantaguzzi & Elizabeth Allen & Alec Miners & Deborah Christie & Charles Opondo & Zia Sadique & Adam Fletcher & Richard Grieve & Chris Bonell & Russell M. Viner & Rosa Legood - 653-661 Estimating an exchange rate between the EQ-5D-3L and ASCOT
by Katherine Stevens & John Brazier & Donna Rowen - 663-673 Choice of reserve capacity by hospitals: a problem for prospective payment
by Philippe K. Widmer & Maria Trottmann & Peter Zweifel - 675-686 Chilean population norms derived from the health-related quality of Life SF-6D
by Miguel A. Garcia-Gordillo & Daniel Collado-Mateo & Pedro R. Olivares & José C. Adsuar - 687-695 Ageing, health status and coverage rate effects on community prescription costs in Ireland
by Martin Kenneally & Brenda Lynch - 697-708 Public acceptability of financial incentives to reward pregnant smokers who quit smoking: a United Kingdom–France comparison
by Noémi Berlin & Léontine Goldzahl & Linda Bauld & Pat Hoddinott & Ivan Berlin - 709-718 Investigating the relationship between costs and outcomes for English mental health providers: a bi-variate multi-level regression analysis
by Valerie Moran & Rowena Jacobs - 719-734 The relationship between diabetes, diabetes-related complications and productive activities among older Europeans
by B. Rodriguez-Sanchez & R. J. M. Alessie & T. L. Feenstra & V. Angelini - 735-746 Cost analysis of colorectal cancer screening with CT colonography in Italy
by Paola Mantellini & Giuseppe Lippi & Lapo Sali & Grazia Grazzini & Silvia Delsanto & Beatrice Mallardi & Massimo Falchini & Guido Castiglione & Francesca Maria Carozzi & Mario Mascalchi & Stefano Milani & Leonardo Ventura & Marco Zappa - 747-756 Smoking, health-related quality of life and economic evaluation
by Ángel López-Nicolás & Marta Trapero-Bertran & Celia Muñoz - 757-768 Can premium differentiation counteract adverse selection in the Dutch supplementary health insurance? A simulation study
by K. P. M. Winssen & R. C. Kleef & W. P. M. M. Ven
May 2018, Volume 19, Issue 4
- 483-487 How can dental insurance be optimized?
by Piet Calcoen & Wynand P. M. M. van de Ven - 489-498 Incorporating equity in economic evaluations: a multi-attribute equity state approach
by Jeff Round & Mike Paulden - 499-519 Primary care supply and quality of care in England
by Laura Vallejo-Torres & Stephen Morris - 521-532 Determinants of catastrophic health expenditure in Nigeria
by Bolaji Samson Aregbeshola & Samina Mohsin Khan - 533-544 Costs associated with community acquired pneumonia in France
by Grèce Saba & Luiz Flavio Andrade & Jacques Gaillat & Pierre Bonnin & Christian Chidiac & Hajnal-Gabriela Illes & Henri Laurichesse & Jonathan Messika & Jean-Damien Ricard & Bruno Detournay & Patrick Petitpretz & Gérard Pouvourville - 545-555 Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan
by Shota Saito & Motoi Azumi & Yusuke Muneoka & Katsuhiko Nishino & Takashi Ishikawa & Yuichi Sato & Shuji Terai & Kouhei Akazawa - 557-570 What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews
by Aureliano Paolo Finch & John Edward Brazier & Clara Mukuria - 571-584 Introduction of therapeutic reference pricing in Slovenia and its economic consequences
by Nika Marđetko & Mitja Kos - 585-594 The financial performance of the health care industry: a global, regional and industry specific empirical investigation
by Gregor Dorfleitner & Felix Rößle - 595-605 Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment
by Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin - 607-626 Autonomy and performance in the public sector: the experience of English NHS hospitals
by Rossella Verzulli & Rowena Jacobs & Maria Goddard - 627-636 Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
by Santiago Grau & Rafael Cámara & Manuel Jurado & Jaime Sanz & Belén Aragón & Irmina Gozalbo
April 2018, Volume 19, Issue 3
- 309-313 The triple challenge of mental health
by Peter Zweifel - 315-325 Emotions and scope effects in the monetary valuation of health
by María V. Avilés Blanco & Raúl Brey & Jorge Araña & José Luis Pinto Prades - 327-340 Economic and public health consequences of delayed access to medical care for migrants living with HIV in France
by Marlène Guillon & Michel Celse & Pierre-Yves Geoffard - 341-353 Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation
by Dirk Müller & Marion Danner & Kerstin Rhiem & Björn Stollenwerk & Christoph Engel & Linda Rasche & Lisa Borsi & Rita Schmutzler & Stephanie Stock - 355-367 The effectiveness of a population-based skin cancer screening program: evidence from Germany
by Micha Kaiser & Jörg Schiller & Christopher Schreckenberger - 369-383 Does socioeconomic status affect lengthy wait time in Canada? Evidence from Canadian Community Health Surveys
by Mohammad Hajizadeh - 385-408 Hospital heterogeneity: what drives the quality of health care
by Manhal Ali & Reza Salehnejad & Mohaimen Mansur - 409-417 Burden of suicide in Poland in 2012: how could it be measured and how big is it?
by Katarzyna Orlewska & Ewa Orlewska - 419-433 Using compensating variation to measure the costs of child disability in the UK
by Mariya Melnychuk & Francesca Solmi & Stephen Morris - 435-446 Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age
by Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög - 447-462 Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis
by Sofia Löfvendahl & Anna Jöud & Ingemar F. Petersson & Elke Theander & Åke Svensson & Katarina Steen Carlsson - 463-470 The socio-economic impact of work disability due to inflammatory bowel disease in Brazil
by Renata S. B. Fróes & Ana Teresa Pugas Carvalho & Antonio Jose V. Carneiro & Adriana Maria Hilu Barros Moreira & Jessica P. L. Moreira & Ronir R. Luiz & Heitor S. de Souza - 471-472 Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”
by Afschin Gandjour - 473-481 Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”
by Alexander Kuhlmann & J.-Matthias Graf Schulenburg
March 2018, Volume 19, Issue 2
- 173-175 The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
by Salah Ghabri & Josephine Mauskopf - 177-187 A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set
by Gareth Thomas - 189-201 The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach
by Grégoire Lagasnerie & Anne-Sophie Aguadé & Pierre Denis & Anne Fagot-Campagna & Christelle Gastaldi-Menager - 203-211 Improving risk equalization using information on physiotherapy diagnoses
by Frank Eijkenaar & René C. J. A. Vliet - 213-222 The impact of physician-level drug budgets on prescribing behavior
by Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt - 223-228 The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany
by Klaus Kaier & Holger Reinecke & Huseyin Naci & Lutz Frankenstein & Martin Bode & Werner Vach & Philip Hehn & Andreas Zirlik & Manfred Zehender & Jochen Reinöhl - 229-240 Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
by Michele R. Wilson & Annika Bergman & Helene Chevrou-Severac & Ross Selby & Michael Smyth & Matthew C. Kerrigan - 241-255 Systematic review of model-based economic evaluations of heart valve implantations
by Simone A. Huygens & Johanna. J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken - 257-266 Association between cultural distance and migrant self-rated health
by Jens Detollenaere & Stijn Baert & Sara Willems - 267-275 Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies
by Erik Nord - 277-291 New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year
by Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer - 293-307 Do healthcare tax credits help poor-health individuals on low incomes?
by Cinzia Di Novi & Anna Marenzi & Dino Rizzi
January 2018, Volume 19, Issue 1
- 1-4 Competition in pharmaceuticals: more product- than price-oriented?
by Livio Garattini & Anna Padula - 5-19 Competition and quality indicators in the health care sector: empirical evidence from the Dutch hospital sector
by R. R. Croes & Y. J. F. M. Krabbe-Alkemade & M. C. Mikkers - 21-35 A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
by Evelina A. Zimovetz & Alain Joseph & Rajeev Ayyagari & Josephine A. Mauskopf - 37-44 Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
by Umberto Restelli & Alfredo Alberti & Adriano Lazzarin & Marzia Bonfanti & Carmela Nappi & Davide Croce - 45-57 Investigating social inequalities in older adults’ dentition and the role of dental service use in 14 European countries
by Jing Shen & Stefan Listl - 59-73 Good jobs, good pay, better health? The effects of job quality on health among older European workers
by Golo Henseke - 75-86 A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations
by Felix Achana & Stavros Petrou & Kamran Khan & Amadou Gaye & Neena Modi - 87-102 Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial
by Bernhard Michalowsky & Steffen Flessa & Tilly Eichler & Johannes Hertel & Adina Dreier & Ina Zwingmann & Diana Wucherer & Henriette Rau & Jochen René Thyrian & Wolfgang Hoffmann - 103-121 A “healthy immigrant effect” or a “sick immigrant effect”? Selection and policies matter
by Amelie F. Constant & Teresa García-Muñoz & Shoshana Neuman & Tzahi Neuman - 123-152 Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
by Aris Angelis & Ansgar Lange & Panos Kanavos - 153-165 Corruption costs lives: evidence from a cross-country study
by Qiang Li & Lian An & Jing Xu & Mina Baliamoune-Lutz - 167-172 Patient preferences: a Trojan horse for evidence-based medicine?
by Afschin Gandjour
December 2017, Volume 18, Issue 9
- 1065-1067 Economic evaluation of personalized medicine: a call for real-world data
by Robert Terkola & Fernando Antoñanzas & Maarten Postma - 1069-1078 Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients
by Amaia Malet-Larrea & Estíbaliz Goyenechea & Miguel A. Gastelurrutia & Begoña Calvo & Victoria García-Cárdenas & Juan M. Cabases & Aránzazu Noain & Fernando Martínez-Martínez & Daniel Sabater-Hernández & Shalom I. Benrimoj - 1079-1093 Out-migration and attrition of physicians and dentists before and after EU accession (2003 and 2011): the case of Hungary
by Júlia Varga - 1095-1105 Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden
by Alessandra Ferrario - 1107-1123 Preferences for public involvement in health service decisions: a comparison between best-worst scaling and trio-wise stated preference elicitation techniques
by Seda Erdem & Danny Campbell - 1125-1135 Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data
by Katharina Bode & Rolf Vogel & Jochen Walker & Christoph Kröger - 1137-1156 Improving risk equalization with constrained regression
by Richard C. Kleef & Thomas G. McGuire & René C. J. A. Vliet & Wynand P. P. M. de Ven - 1157-1179 Gender-specific practice styles and ambulatory health care expenditures
by Boris Kaiser - 1181-1198 A methodological proposal to evaluate the cost of duration moral hazard in workplace accident insurance
by Ángel Martín-Román & Alfonso Moral
November 2017, Volume 18, Issue 8
- 933-936 Market approval for drugs in the EU: time to change direction?
by Alessandro Curto & Katelijne de Vooren & Livio Garattini - 937-965 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies
by Alexandre Baptista & Inês Teixeira & Sónia Romano & António Vaz Carneiro & Julian Perelman - 967-977 Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale
by Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard - 979-986 Costs of dementia in the Czech Republic
by Iva Holmerová & Jakub Hort & Robert Rusina & Anders Wimo & Michal Šteffl - 987-1000 A method to simulate incentives for cost containment under various cost sharing designs: an application to a first-euro deductible and a doughnut hole
by D. Cattel & R. C. Kleef & R. C. J. A. Vliet - 1001-1011 Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies
by Hayley Bennett & Jason Gordon & Beverley Jones & Thomas Ward & Samantha Webster & Anupama Kalsekar & Yong Yuan & Michael Brenner & Phil McEwan - 1013-1030 Junior doctors’ medical specialty and practice location choice: simulating policies to overcome regional inequalities
by Pedro Ramos & Hélio Alves & Paulo Guimarães & Maria A. Ferreira - 1031-1039 The impact of minimum wages on population health: evidence from 24 OECD countries
by Otto Lenhart - 1041-1046 Cost effects of preterm birth: a comparison of health care costs associated with early preterm, late preterm, and full-term birth in the first 3 years after birth
by Josephine Jacob & Moritz Lehne & Andrea Mischker & Normen Klinger & Claudia Zickermann & Jochen Walker - 1047-1064 Switching gains and health plan price elasticities: 20 years of managed competition reforms in The Netherlands
by Rudy Douven & Katalin Katona & Frederik Schut & Victoria Shestalova
September 2017, Volume 18, Issue 7
- 801-803 On vaccination programs in the EU Member States: the case of the human papilloma virus
by Reyes Lorente & Fernando Antonanzas - 805-830 Healthier lifestyles after retirement in Europe? Evidence from SHARE
by Martina Celidoni & Vincenzo Rebba - 831-845 Measuring customer preferences in the German statutory health insurance
by Jonas B. Pendzialek & Dusan Simic & Stephanie Stock - 847-858 The social cost of chronic kidney disease in Italy
by Giuseppe Turchetti & S. Bellelli & M. Amato & S. Bianchi & P. Conti & A. Cupisti & V. Panichi & A. Rosati & F. Pizzarelli - 859-867 Does drug price-regulation affect healthcare expenditures?
by Omer Ben-Aharon & Oren Shavit & Racheli Magnezi - 869-882 Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort
by Dmitrij Achelrod & Jonas Schreyögg & Tom Stargardt - 883-892 The social cost of drugs in France in 2010
by Pierre Kopp & Marysia Ogrodnik - 893-904 Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
by Peter Greven & Vanja Sikirica & Yaozhu J. Chen & Tammy G. Curtice & Charles Makin - 905-919 The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program
by Anne Neumann & Lars Lindholm & Margareta Norberg & Olaf Schoffer & Stefanie J. Klug & Fredrik Norström - 921-932 Age effects in mortality risk valuation
by Raul Brey & Jose Luis Pinto-Prades
July 2017, Volume 18, Issue 6
- 667-670 The enigma of value: in search of affordable and accessible health care
by Thomas D. Szucs & Martina Weiss & Guido Klaus - 671-683 How important is severity for the evaluation of health services: new evidence using the relative social willingness to pay instrument
by Jeff Richardson & Angelo Iezzi & Aimee Maxwell - 685-696 Evaluating the consequences of rheumatoid arthritis
by Björn Sossong & Stefan Felder & Malte Wolff & Klaus Krüger - 697-701 A comparison of average wages with age-specific wages for assessing indirect productivity losses: analytic simplicity versus analytic precision
by Mark P. Connolly & Cole Tashjian & Nikolaos Kotsopoulos & Aomesh Bhatt & Maarten J. Postma - 703-713 The costs of hazardous alcohol consumption in Germany
by Tobias Effertz & Frank Verheyen & Roland Linder - 715-730 Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries
by Elena Nicod - 731-742 Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients
by L. T. Burgers & W. K. Redekop & M. J. Al & S. K. Lhachimi & N. Armstrong & S. Walker & C. Rothery & M. Westwood & J. L. Severens - 743-760 The impact of the design of payment scales on the willingness to pay for health gains
by Lotte Soeteman & Job Exel & Ana Bobinac - 761-771 Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK
by Diana Weidlich & Fredrik L. Andersson & Matthias Oelke & Marcus John Drake & Aino Fianu Jonasson & Julian F. Guest - 773-785 China’s medical savings accounts: an analysis of the price elasticity of demand for health care
by Hao Yu - 787-799 Waist circumference, body mass index, and employment outcomes
by Jonas Minet Kinge
June 2017, Volume 18, Issue 5
- 533-536 Access, use, and challenges of claims data analyses in Germany
by Sarah Neubauer & Kristine Kreis & Mike Klora & Jan Zeidler - 537-546 The impact of race, income, drug abuse and dependence on health insurance coverage among US adults
by Nianyang Wang & Xin Xie - 547-565 Healthcare inequality issues among immigrant elders after neoliberal welfare reform: empirical findings from the United States
by Younsook Yeo - 567-574 The dynamic relationship between health expenditure and economic growth: is the health-led growth hypothesis valid for Turkey?
by Emre Atilgan & Dilek Kilic & Hasan Murat Ertugrul - 575-585 Societal costs of fetal alcohol syndrome in Sweden
by Lisa Ericson & Lennart Magnusson & Bo Hovstadius - 587-608 Measuring the efficiency of large pharmaceutical companies: an industry analysis
by Fernando Gascón & Jesús Lozano & Borja Ponte & David Fuente - 609-621 Impact assessment of a pay-for-performance program on breast cancer screening in France using micro data
by Jonathan Sicsic & Carine Franc - 623-633 Cost analysis of whole genome sequencing in German clinical practice
by Marika Plöthner & Martin Frank & J.-Matthias Graf Schulenburg - 635-647 Measuring the productivity of residential long-term care in England: methods for quality adjustment and regional comparison
by Wei Yang & Julien Forder & Olena Nizalova - 649-665 The effects of organized screening programs on the demand for mammography in Switzerland
by Mark Pletscher
May 2017, Volume 18, Issue 4
- 399-404 A perspective on the health care expenditures for defensive medicine
by Michael Osti & Johannes Steyrer - 405-415 Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
by Fredrik Salvesen Haukaas & Trude Margrete Arnesen & Brita Askeland Winje & Eline Aas